Progress in neoadjuvant therapy for gastric cancer (Review)
- Authors:
- Peng-Fei Su
- Jian-Chun Yu
-
Affiliations: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China - Published online on: April 13, 2022 https://doi.org/10.3892/ol.2022.13292
- Article Number: 172
-
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Global Burden of Disease Cancer Collaboration, . Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chandra R, Balachandar N, Wang S, Reznik S, Zeh H and Porembka M: The changing face of gastric cancer: Epidemiologic trends and advances in novel therapies. Cancer Gene Ther. 28:390–399. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yin S, Wang P, Xu X, Tan Y, Huang JY and Xu HM: The optimal strategy of multimodality therapies for resectable gastric cancer: Evidence from a network meta-analysis. J Cancer. 10:3094–3101. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Hu D, Li W and Yu XJ: Neoadjuvant chemotherapy brings more survival benefits than postoperative chemotherapy for resectable gastric cancer: A meta-analysis of randomized controlled trials. J BUON. 24:201–214. 2019.PubMed/NCBI | |
|
Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC and Roses RE: Neoadjuvant therapy for gastric cancer: Current evidence and future directions. J Gastrointest Oncol. 6:534–543. 2015.PubMed/NCBI | |
|
Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van Krieken JH and van de Velde C: Chemotherapy for operable gastric cancer: Results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 35:558–562. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hartgrink HH, Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J and van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group, : Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 30:643–649. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, et al: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 28:5210–5218. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, et al: Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): An open-label, randomised phase 3 trial. Lancet Oncol. 18:1249–1260. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, et al: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29:1715–1721. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Batran S, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, et al: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Batran S, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, et al: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 393:1948–1957. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
National Comprehensive Cancer Network (NCCN), . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric cancer (version 2). NCCN; Plymouth Meeting, PA: 2018, www.nccn.orgMay 22–2018 | |
|
Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, Wu Q, Zong XL, Ren H, Tang L, et al: Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 105:793–799. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Takayama Y, Suda H and Takayama T: Phase II study of neoadjuvant chemotherapy with S-1 and CDDP in patients with lymph Node metastatic stage II or III gastric cancer. Am J Clin Oncol. 40:17–21. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, et al: Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 22:1044–1052. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, et al: Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): An open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 22:1081–1092. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 (Suppl 5):v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang FH, Zhang XT, Li F, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y and Kinugasa Y: Perioperative chemotherapy for locally advanced gastric cancer in Japan: Current and future perspectives. Surg Today. 50:30–37. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, et al: Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 62:103–111. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H and Budach W: Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 81:183–190. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27:851–856. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, et al: A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 27:660–667. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al: Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, et al: TOPGEAR: A randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 24:2252–2258. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraja AK, Kikuchi O and Bass AJ: Genomics and targeted therapies in gastroesophageal adenocarcinoma. Cancer Discov. 9:1656–1672. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Patel TH and Cecchini M: Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 21:702020. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, et al: Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial. BMC Cancer. 16:682016. View Article : Google Scholar : PubMed/NCBI | |
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 29:3968–3976. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: Randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 18:168–176. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Keam SJ: Trastuzumab deruxtecan: First approval. Drugs. 80:501–508. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, et al: Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol. 18:357–370. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Y, Yang X, Yan C, Feng R, Sah BK, Yang Z, Zhu Z, Liu W, Xu W, Ni Z, et al: Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. Eur J Cancer. 130:12–19. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx K, Pohl M, et al: Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phaseII trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 149:1322–1331. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, et al: EORTC-1203-GITCG-the ‘INNOVATION’-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 19:4942019. View Article : Google Scholar : PubMed/NCBI | |
|
Chiari D, Orsenigo E, Guarneri G, Baiocchi GL, Mazza E, Albarello L, Bissolati M, Molfino S and Staudacher C; Gruppo Italiano Ricerca Cancro Gastrico (GIRCG), : Effect of neoadjuvant chemotherapy on HER-2 expression in surgically treated gastric and oesophagogastric junction carcinoma: A multicentre Italian study. Updates Surg. 69:35–43. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bozkaya Y, Özdemir NY, Sezer S, Köstek O, Demirci NS, Yazıcı O, Erdem GU, Eren T and Zengin N: Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy? Cancer Biomark. 22:143–149. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, Guo J, Qin R, Qin W and Gu J: Distribution of IgG galactosylation as a promising biomarker for cancer screening in multiple cancer types. Cell Res. 26:963–966. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qin R, Yang Y, Qin W, Han J, Chen H, Zhao J, Zhao R, Li C, Gu Y, Pan Y, et al: The value of serum immunoglobulin G glycome in the preoperative discrimination of peritoneal metastasis from advanced gastric cancer. J Cancer. 10:2811–2821. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Qin R, Yang Y, Chen H, Qin W, Han J, Gu Y, Pan Y, Cheng X, Zhao J, Wang X, et al: Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clin Proteomics. 17:42020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan B, Li Y, Di Y, Fan L, Zhao Q, Liu Q, Wang D and Jia N: Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. J Clin Lab Anal. 32:e223632018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu C, Cheng H, Li N, Zhou N and Tang X: Relationship between microRNA-27a and efficacy of neoadjuvant chemotherapy in gastric cancer and its mechanism in gastric cancer cell growth and metastasis. Biosci Rep. 39:BSR201811752019. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Izquierdo N, Perlaza P, Pagès M, Buxó E, Rios J, Rubello D, Colletti PM, Mayoral M, Casanueva S, Fernández-Esparrach G, et al: Assessment of response to neoadjuvant chemoradiotherapy by 18F-FDG PET/CT in patients with locally advanced esophagogastric junction adenocarcinoma. Clin Nucl Med. 45:38–43. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JW, Jo K, Cho A, Noh SH, Lee JD and Yun M: Relationship between 18F-FDG uptake on PET and recurrence patterns after curative surgical resection in patients with advanced gastric cancer. J Nucl Med. 56:1494–1500. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Zhou X, Liu JJ and Huang G: Relationship between18F-FDG PET/CT findings and HER2 expression in gastric cancer. J Nucl Med. 57:1040–1044. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Liang JX, Bi XJ, Li XM, Gao ZL, Suo F, Cui EG, Li HF and Lv HL: Evaluation of multislice spiral computed tomography perfusion imaging for the efficacy of preoperative concurrent chemoradiotherapy in middle-aged and elderly patients with locally advanced gastric cancer. Med Sci Moni. 24:235–245. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang P, Li S, Aronow WS, Wang Z, Nair CK, Xue N, Shen X, Chen C and Cosgrove D: Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma. Arch Med Sci. 7:287–293. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H and Hofler H: Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas. Ann Surg. 253:934–939. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, . (3rd English edition). Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, et al: Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 34:2721–2727. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G and Barni S: Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 43:1607–1616. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC and Koom WS: Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol. 21:2711–2718. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Leong T: A CRITICal period for chemoradiotherapy in gastric cancer. Lancet Oncol. 19:581–583. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A and Al-Batran SE: Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev. 69:90–100. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, et al: Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol. 19:616–628. 2018. View Article : Google Scholar : PubMed/NCBI |
